NCT Number: NCT00507403
Infliximab and Methotrexate in Ankylosing Spondylitis
There is a great individual variability of pharmacokinetic of infliximab in patients treated for ankylosing spondylitis (AS). Moreover, some patients have a treatment with methotrexate (MTX), others have not.
Thus, the aim of this study is to assess the effect of MTX on the pharmacokinetic properties of infliximab in 30 patients treated for AS, 15 with MTX, 15 without.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
University Hospital Jean MINJOZ -Besançon, Besançon, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Ankylosing spondylitis
- Needing anti-TNF drugs
Exclusion criteria
- Contra-indications to anti-TNF drugs
Treatment and study plan
Primary outcomes
-
Pharmacokinetic properties of infliximab in AS patients with or without methotrexate
Time frame: 16 weeks
Secondary outcomes
-
Individual pharmacokinetic modelisation of infliximab
Time frame: 16 weeks
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
University Hospital, Tours
Other
Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France
Registry information
Official study title
Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis
Acronym: SPAXIM
Important dates
- Study start
- 2007
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Jul 26, 2007
- Registry last updated
- Jan 16, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
NCT03928743
Ankylosing Spondylitis, Ankylosis
Mesa, Arizona, United States
View Trial DetailsExtension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
NCT05861128
Ankylosing Spondylitis, Ankylosis
Shanghai, Shanghai Municipality, China
View Trial DetailsEfficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
NCT05861102
Ankylosing Spondylitis, Ankylosis
Shanghai, Shanghai Municipality, China
View Trial DetailsLacticaseibacillus Rhamnosus GG Supplementation in Active Ankylosing Spondylitis
NCT07834788
Ankylosing Spondylitis, Ankylosis
Adana, Balcalı, Turkey (Türkiye)
View Trial Details